New drug combo aims to wipe out breast cancer before surgery
NCT ID NCT04290793
Summary
This study is testing a new treatment approach for early-stage HER2-positive breast cancer. It combines an experimental drug called pyrotinib with standard chemotherapy drugs, all given before surgery. The goal is to see if this combination can more effectively shrink or eliminate the tumor, potentially leading to better long-term results for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Conditions
Explore the condition pages connected to this study.